Research estimates myopia will affect 50% of the world by 2050, and recent COVID lockdowns appear to have only worsened the situation. As more patients – and their parents – seek effective interventions, practitioners should prepare to meet this oncoming public health demand. Read more
New anti-VEGF therapies seeking Aussie approval
The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian Pharmaceutical Benefits Scheme (PBS). Read more
Understanding new treatment protocols for severe dry eye
At the completion of this CPD activity, optometrists will have developed their knowledge of treatment options for severe dry eye disease. Including:
- Understand the use of anti-inflammatory agents in the treatment of extreme dry eye
- Understand the benefits and contraindications for treatment of dry eye with topical ciclosporin and lifitegrast
- Understand the benefits, indications and contraindications of amniotic membrane therapy for dry eye
NOTE: Optomery Australia members can enter their details at the bottom of this article to have it automatically added to their Learning Plan. Read more
SightGlass Vision specs’ two-year data demonstrates myopia control efficacy
Spectacles that use SightGlass Vision’s trademarked Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children, based on 24-month interim data from its pivotal multisite clinical study. Read more
New five-year data for MIGS device
Half a decade of data on the second generation iStent inject has shown a significant reduction in intraocular pressure (IOP) and medication burden in glaucoma patients. Read more
Nova Eye Medical officially launches next-gen iTrack Advance
ASX-listed ophthalmic technology company Nova Eye Medical expects more cataract surgeons and comprehensive ophthalmologists to uptake its glaucoma canaloplasty procedure, with the launch of its improved iTrack device in select Europe and Asia Pacific markets this week. Read more
Glaukos commences trials for its third-generation keratoconus therapy
Glaukos has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Read more
Covering all bases of myopia management
Myopia’s prevalence has spawned all-new innovation and unexpected collaborations. One of those is a three-way company alliance promising Australian optometrists a new one-two approach to myopia management. Read more
Funding for Luxturna following MSAC recommendation
Luxturna has become the first gene therapy to receive government funding in Australia, in a landmark decision that will see the treatment jointly funded by federal and state governments. Read more
Clinic becomes Australia’s first to offer latest in LASIK tech
Australian ophthalmology network PersonalEYES has become the nation’s first to offer a breakthrough method of measuring and combining data to generate a multi-dimensional model of the eye for more precise laser eye treatment. Read more